What Are the Therapeutic Strategies for BRAF-Mutant Cancers?
Targeted therapies have been developed to inhibit the activity of the mutated BRAF protein. BRAF inhibitors such as vemurafenib and dabrafenib are designed to specifically target and inhibit the mutant BRAF V600E protein. Additionally, MEK inhibitors, which block downstream components of the MAPK/ERK pathway, are often used in combination with BRAF inhibitors to improve treatment efficacy and overcome resistance.
